ClinicalTrials.gg
CompletedNCT03783078Updated May 28, 2025Results posted

Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)

A Phase 3 interventional study of Pembrolizumab (MK-3475) in Merkel Cell Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in 8 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pembrolizumab in Carcinoma, Merkel Cell — 4 open to participants now, 6 under way, 1 of them phase 3. pembrolizumab · Carcinoma, Merkel Cell.

Enrollment
3rd of 11
55 · median 26
Started
2019
with 2 others
Phase 3
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
2 of 11
Merck Sharp & Dohme LLC

Among the 11 studies testing pembrolizumab in Carcinoma, Merkel Cell, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 3rd registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 40 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

4 of the 11 studies testing pembrolizumab in Carcinoma, Merkel Cell are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 34 Carcinoma, Merkel Cell studies recruiting now, 27 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing pembrolizumab in Carcinoma, Merkel Cell, or all of them as a file.
02

Study summary

This is a single-arm, open-label, multicenter, efficacy, and safety study of pembrolizumab in adult and pediatric participants with previously untreated advanced Merkel Cell Carcinoma (MCC). The primary objective of the trial is to assess the objective response rate, as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, following administration of pembrolizumab.

03

Conditions studied

  • Merkel Cell Carcinoma

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)
  • Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
  • Merkel cell carcinoma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be male or female and at least 12 years of age, at the time of signing the /assent.
  • Have confirmed diagnosis of locoregional MCC that has recurred following standard locoregional therapy with surgery and/or radiation therapy and is not amenable to local therapy or MCC (Stage IV) as per American Joint Committee on Cancer (AJCC) 8th edition guidelines.
  • Have been untreated for advanced or metastatic disease except as follows:

    1. Prior intratumoral therapy will be permitted.
    2. Prior or neoadjuvant therapy containing systemic chemotherapy will be permitted if treatment concluded at least 3 months prior to Cycle 1 Day 1 (C1D1).
    3. Prior adjuvant or neoadjuvant therapy containing /L1 or anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) therapy will not be permitted.
  • Have at least 1 by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1 criteria as determined by the local site investigator/radiology assessment.
  • Toxic effect(s) of the most recent prior therapy have resolved to Grade 1 or less (except alopecia).
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
  • Is not a woman of (WOCBP)
  • OR
  • Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis).
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 72 hours before the first dose of study intervention.
  • Have an (ECOG) performance status of 0 or 1 or Lansky Play-Performance Scale (LPS) ≥50 for pediatric participants up to and including 16 years of age.
  • Have adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment within the past 2 years with certain exceptions.
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis with certain exceptions.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to C1D1.
  • Has severe (≥Grade 3) to pembrolizumab and/or any of its .
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs).
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Has an active infection requiring systemic therapy.
  • Has a known history of (HIV) infection.
  • Has a known history of (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active virus (defined as HCV RNA [qualitative] is detected) infection.
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
  • Has cardiac disease within 6 months of C1D1, including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Has not received standard locoregional therapy with surgery and/or radiation therapy for the treatment of local or locoregional disease. Note: This exclusion criterion does not apply to participants who are diagnosed with unresectable or metastatic MCC.
  • Has received prior therapy with an , anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
  • Has received prior systemic anticancer therapy including agents within 12 weeks prior to C1D1.
  • Has received radiotherapy within 2 weeks prior to start of study intervention.
  • Has received a within 30 days prior to C1D1.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to C1D1.
  • Has had an allogenic tissue/solid organ transplant.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Pembrolizumab

    Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)

    Drug: Pembrolizumab (MK-3475)

Interventions

  • 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) IV up to 35 administrations (approximately 2 years).

    Also known as: MK-3475

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The percentage of participants who experienced CR or PR as assessed by blinded independent central review (BICR) were presented.

    Time frame: Up to ~34 months

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

    Time frame: Up to ~58 months

  2. Progression-free Survival (PFS)

    Progression-Free Survival was defined as the time from the first dose of study treatment to the first documented evidence of disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

    Time frame: Up to ~58 months

  3. Overall Survival (OS)

    OS was defined as the time from the first dose of study treatment until death from any cause.

    Time frame: Up to ~58 months

  4. Number of Participants With One or More Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.

    Time frame: Up to ~58 months

  5. Number of Participants Who Discontinued From Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE was assessed.

    Time frame: Up to ~27 months

07

Results

Posted Feb 17, 2023

Participant flow

Participants of at least 12 years of age with advanced Merkel cell carcinoma (MCC) were recruited to evaluate the safety and efficacy of Pembrolizumab (MK-3475) as first-line therapy.

Participant flow — Overall Study
MilestonePembrolizumab 200 mg
Started55
Completed0
Not completed55
Withdrew: Death31
Withdrew: Sponsor decision23
Withdrew: Withdrawal by parent/guardian1

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The percentage of participants who experienced CR or PR as assessed by blinded independent central review (BICR) were presented.

Time frame:
Up to ~34 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsPembrolizumab 200 mg
Objective Response Rate (ORR)49.1 (35.4 to 62.9)
SecondaryDuration of Response (DOR)

For participants who demonstrated a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

Time frame:
Up to ~58 months
Reported as:
Median · Months
Duration of Response (DOR)
MonthsPembrolizumab 200 mg
Duration of Response (DOR)39.8 (23.8 to NA)
SecondaryProgression-free Survival (PFS)

Progression-Free Survival was defined as the time from the first dose of study treatment to the first documented evidence of disease progression per RECIST 1.1 by BICR or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

Time frame:
Up to ~58 months
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsPembrolizumab 200 mg
Progression-free Survival (PFS)9.3 (3.0 to 25.5)
SecondaryOverall Survival (OS)

OS was defined as the time from the first dose of study treatment until death from any cause.

Time frame:
Up to ~58 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab 200 mg
Overall Survival (OS)24.3 (12.4 to NA)
SecondaryNumber of Participants With One or More Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE was assessed.

Time frame:
Up to ~58 months
Reported as:
Count of participants · Participants
Number of Participants With One or More Adverse Events (AEs)
ParticipantsPembrolizumab 200 mg
Number of Participants With One or More Adverse Events (AEs)52
SecondaryNumber of Participants Who Discontinued From Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued from study treatment due to an AE was assessed.

Time frame:
Up to ~27 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued From Study Treatment Due to an AE
ParticipantsPembrolizumab 200 mg
Number of Participants Who Discontinued From Study Treatment Due to an AE18

Adverse events

Collected over Up to ~58 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab 200 mg32/55 (58.2%)24/55 (43.6%)49/55 (89.1%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPembrolizumab 200 mg
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/55
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/55
ColitisGastrointestinal disorders1/55
DysphagiaGastrointestinal disorders1/55
Obstructive pancreatitisGastrointestinal disorders1/55
Small intestinal obstructionGastrointestinal disorders1/55
SubileusGastrointestinal disorders1/55
FatigueGeneral disorders1/55
CellulitisInfections and infestations1/55
CystitisInfections and infestations1/55
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPembrolizumab 200 mg
FatigueGeneral disorders14/55
PruritusSkin and subcutaneous tissue disorders13/55
Aspartate aminotransferase increasedInvestigations12/55
AstheniaGeneral disorders11/55
Alanine aminotransferase increasedInvestigations10/55
Lipase increasedInvestigations10/55
ArthralgiaMusculoskeletal and connective tissue disorders10/55
AnaemiaBlood and lymphatic system disorders9/55
ConstipationGastrointestinal disorders9/55
Back painMusculoskeletal and connective tissue disorders9/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab 200 mg
Mean72.5 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab 200 mg
Female24
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab 200 mg
Hispanic or Latino0
Not Hispanic or Latino35
Unknown or Not Reported20
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab 200 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White39
More than one race0
Unknown or Not Reported16
08

Study locations

22 sites
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0006)
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai ( Site 0004)
    New York, New York 10029, United States
  • Melanoma Institute Australia ( Site 0400)
    North Sydney, New South Wales 2065, Australia
  • Calvary Mater Newcastle ( Site 0402)
    Waratah, New South Wales 2298, Australia
  • Moncton Hospital - Horizon Health Network ( Site 0055)
    Moncton, New Brunswick E1C 6Z8, Canada
  • Princess Margaret Cancer Centre ( Site 0051)
    Toronto, Ontario M5G 2M9, Canada
  • Hopital de la Cote de Nacre - Caen ( Site 0204)
    Caen, Calvados 14033, France
  • CHU de Bordeaux- Hopital Saint Andre ( Site 0203)
    Bordeaux, Gironde 33000, France
  • Hopital Ambroise Pare Boulogne ( Site 0201)
    Boulogne-Billancourt, Hauts-de-Seine 92100, France
  • C.H.R.U. de Tours. Hopital Trousseau ( Site 0202)
    Chambray Les Tours, Indre-et-Loire 37170, France
  • CHRU Lille - Hopital Claude Huriez ( Site 0200)
    Lille, Nord 59037, France
  • Azienda Ospedaliera Universitaria Senese ( Site 0224)
    Siena, Toscana 53100, Italy
  • IEO Istituto Europeo di Oncologia ( Site 0223)
    Milano, 20141, Italy
  • Istituto Nazionale Tumori Fondazione Pascale ( Site 0222)
    Napoli, 80131, Italy
  • Istituto Oncologico Veneto ( Site 0221)
    Padova, 35128, Italy
  • Auckland City Hospital ( Site 0427)
    Auckland, 1023, New Zealand
  • Hospital General Universitario de Valencia ( Site 0262)
    Valencia, Valenciana, Comunitat 46014, Spain
  • Hospital Universitari Vall d Hebron ( Site 0264)
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona ( Site 0261)
    Barcelona, 08036, Spain
  • Hospital Universitario La Paz ( Site 0263)
    Madrid, 28046, Spain
  • Karolinska Universitetssjukhuset Solna ( Site 0281)
    Solna, Stockholms Lan 171 64, Sweden
  • Sahlgrenska Universitetssjukhuset ( Site 0282)
    Goeteborg, Vastra Gotalands Lan 413 45, Sweden
09

References and documents

Publications

  • Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V. Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. Am J Clin Dermatol. 2024 Nov;25(6):987-996. doi: 10.1007/s40257-024-00885-w. Epub 2024 Oct 8. PubMed 39377880 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Feb 2022, 35 months.

Results were first posted in Feb 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2018
First posted
Dec 20, 2018
StartActual
Feb 25, 2019
Primary completionActual
Feb 15, 2022
CompletionActual
Feb 15, 2024
Results first posted
Feb 17, 2023
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03783078
Responsible party
Sponsor
First posted
Dec 20, 2018
Start date
Feb 25, 2019
Primary completion
Feb 15, 2022
Completion
Feb 15, 2024
Results posted
Feb 17, 2023
Last update
May 28, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion